What is Zephyr AI?
Zephyr AI operates at the intersection of big data and clinical research, positioning itself as a critical infrastructure provider for the next generation of healthcare. The company is currently curating one of the world's most comprehensive healthcare datasets, which serves as the foundation for its proprietary AI algorithms. By generating translatable insights that support both patients and providers, Zephyr AI is effectively bridging the gap between raw biological data and actionable clinical outcomes. Its mission-focused approach, supported by a team of world-class engineers and biologists, has enabled the firm to build enduring partnerships that are fundamentally reshaping how complex diseases are diagnosed and treated on a global scale.
How much funding has Zephyr AI raised?
Zephyr AI has raised a total of $189.5M across 3 funding rounds:
Angel/Seed
$18.5M
Series A
$111M
Private Equity
$60M
Angel/Seed (2022): $18.5M with participation from Medstar Health, Lerner Group Investments, Allen Chao, Boxgroup Ventures, and AME Cloud Ventures
Series A (2024): $111M led by Revolution Growth, Lilly, and Epiq Capital Group
Private Equity (2024): $60M supported by Elda River Capital Management and The Pritzker Organization
Key Investors in Zephyr AI
Revolution Growth
A growth-focused investment firm that partners with extraordinary entrepreneurs to scale niche ideas into mass-market, multi-billion dollar enterprises.
Lilly
A global biopharmaceutical leader dedicated to research-driven innovation in oncology, immunology, and neuroscience.
Epiq Capital Group
A Silicon Valley-based multi-family office and institutional investment manager providing tailored financial solutions for high-net-worth families and institutions.
What's next for Zephyr AI?
With the successful completion of this major strategic investment, Zephyr AI is well-positioned to scale its operations and deepen its research capabilities. The company's roadmap likely involves expanding its data curation efforts and enhancing its AI-driven product suite to address broader therapeutic areas. As it transitions from its earlier development phases into a more mature enterprise-level entity, the focus will remain on translating complex data into clinical tools that drive efficiency and improve patient outcomes. The continued support from high-profile institutional backers suggests a strong market confidence in the company's ability to disrupt the multi-billion dollar healthcare landscape through technological innovation.
See full Zephyr AI company page
